Hong Hyun Sook, Hwang Dae Yeon, Park Ju Hyeong, Kim Suna, Seo Eun Jung, Son Youngsook
College of Medicine/East-West Medical Research Institute, Kyung Hee University, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
Department of Medicine, Graduate School, Kyung Hee University, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
Cytokine. 2017 Feb;90:21-30. doi: 10.1016/j.cyto.2016.10.002. Epub 2016 Oct 14.
Intestinal inflammation alters immune responses in the mucosa and destroys colon architecture, leading to serious diseases such as inflammatory bowel disease (IBD). Thus, regulation of inflammation is regarded as the ultimate therapy for intestinal disease. Substance-P (SP) is known to mediate proliferation, migration, and cellular senescence in a variety of cells. SP was found to mobilize stem cells from bone marrow to the site of injury and to suppress inflammatory responses by inducing regulatory T cells (Tregs) and M2 macrophages. In this study, we explored the effects of SP in a dextran sodium sulfate (DSS)-induced intestine damage model. The effects of SP were evaluated by analyzing crypt structures, proliferating cells within the colon, cytokine secretion profiles, and immune cells population in the spleen/mesenteric lymph nodes in vivo. DSS treatment provoked an inflammatory response with loss of crypts in the intestines of experimental mice. This response was associated with high levels of inflammatory cytokines such as TNF-α and IL-17, and low levels of Tregs and M2 macrophages, leading to severely damaged tissue structure. However, SP treatment inhibited inflammatory responses by modulating cytokine production as well as the balance of Tregs/Th 17 cells and the M1/M2 transition in lymphoid organs, leading to accelerated tissue repair. Collectively, our data indicate that SP can promote the regeneration of tissue following damage by DSS treatment, possibly by modulating immune response. Our results propose SP as a candidate therapeutic for intestine-related inflammatory diseases.
肠道炎症会改变黏膜中的免疫反应并破坏结肠结构,从而引发诸如炎症性肠病(IBD)等严重疾病。因此,炎症调节被视为肠道疾病的最终治疗方法。已知P物质(SP)可介导多种细胞的增殖、迁移和细胞衰老。研究发现,SP能将骨髓中的干细胞动员至损伤部位,并通过诱导调节性T细胞(Tregs)和M2巨噬细胞来抑制炎症反应。在本研究中,我们探讨了SP在葡聚糖硫酸钠(DSS)诱导的肠道损伤模型中的作用。通过分析隐窝结构、结肠内的增殖细胞、细胞因子分泌谱以及体内脾脏/肠系膜淋巴结中的免疫细胞群体来评估SP的作用。DSS处理引发了实验小鼠肠道隐窝丢失的炎症反应。这种反应与高水平的炎症细胞因子如TNF-α和IL-17以及低水平的Tregs和M2巨噬细胞有关,导致组织结构严重受损。然而,SP处理通过调节细胞因子产生以及Tregs/Th 17细胞平衡和淋巴器官中的M1/M2转变来抑制炎症反应,从而加速组织修复。总体而言,我们的数据表明,SP可能通过调节免疫反应促进DSS处理后受损组织的再生。我们的结果表明SP可作为肠道相关炎症性疾病的候选治疗药物。